Cary Street Partners Financial LLC Invests $482,000 in Agilent Technologies, Inc. (NYSE:A)

Cary Street Partners Financial LLC acquired a new stake in Agilent Technologies, Inc. (NYSE:A - Free Report) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 3,585 shares of the medical research company's stock, valued at approximately $482,000.

Other hedge funds have also made changes to their positions in the company. CKW Financial Group grew its holdings in shares of Agilent Technologies by 114.9% during the fourth quarter. CKW Financial Group now owns 187 shares of the medical research company's stock valued at $25,000 after buying an additional 100 shares in the last quarter. Global X Japan Co. Ltd. increased its holdings in shares of Agilent Technologies by 161.1% in the 4th quarter. Global X Japan Co. Ltd. now owns 188 shares of the medical research company's stock valued at $25,000 after purchasing an additional 116 shares during the period. Redwood Park Advisors LLC acquired a new stake in shares of Agilent Technologies during the fourth quarter worth approximately $27,000. Lee Danner & Bass Inc. acquired a new position in Agilent Technologies in the 4th quarter valued at approximately $29,000. Finally, Hanson & Doremus Investment Management boosted its stake in shares of Agilent Technologies by 66.5% during the 4th quarter. Hanson & Doremus Investment Management now owns 263 shares of the medical research company's stock valued at $35,000 after buying an additional 105 shares during the period.

Agilent Technologies Price Performance

NYSE A traded down $0.03 during midday trading on Tuesday, hitting $115.52. The company had a trading volume of 2,748,263 shares, compared to its average volume of 1,897,049. The firm has a 50-day moving average price of $111.31 and a 200-day moving average price of $128.66. The company has a market capitalization of $32.93 billion, a PE ratio of 26.56, a P/E/G ratio of 3.01 and a beta of 1.27. The company has a current ratio of 2.20, a quick ratio of 1.66 and a debt-to-equity ratio of 0.56. Agilent Technologies, Inc. has a twelve month low of $96.43 and a twelve month high of $155.35.

Agilent Technologies (NYSE:A - Get Free Report) last released its quarterly earnings data on Wednesday, February 26th. The medical research company reported $1.31 earnings per share for the quarter, beating the consensus estimate of $1.27 by $0.04. The business had revenue of $1.68 billion for the quarter, compared to analyst estimates of $1.67 billion. Agilent Technologies had a return on equity of 25.56% and a net margin of 19.27%. As a group, analysts anticipate that Agilent Technologies, Inc. will post 5.54 earnings per share for the current fiscal year.

Agilent Technologies Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Wednesday, April 23rd. Shareholders of record on Tuesday, April 1st were paid a $0.248 dividend. This represents a $0.99 annualized dividend and a yield of 0.86%. The ex-dividend date of this dividend was Tuesday, April 1st. Agilent Technologies's dividend payout ratio (DPR) is presently 22.76%.

Wall Street Analyst Weigh In

A has been the topic of a number of research reports. Barclays dropped their price objective on Agilent Technologies from $138.00 to $115.00 and set an "equal weight" rating on the stock in a report on Thursday, April 10th. Jefferies Financial Group cut their target price on Agilent Technologies from $135.00 to $116.00 and set a "hold" rating on the stock in a report on Monday, April 21st. Wells Fargo & Company lowered their price objective on Agilent Technologies from $155.00 to $135.00 and set an "overweight" rating on the stock in a report on Thursday, April 17th. Robert W. Baird reduced their target price on Agilent Technologies from $161.00 to $159.00 and set an "outperform" rating for the company in a report on Thursday, February 27th. Finally, TD Cowen upped their price target on shares of Agilent Technologies to $135.00 and gave the company a "buy" rating in a report on Thursday, April 10th. Seven research analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $143.00.

Insiders Place Their Bets

In other Agilent Technologies news, VP Rodney Gonsalves sold 1,908 shares of the firm's stock in a transaction on Monday, March 17th. The stock was sold at an average price of $121.98, for a total value of $232,737.84. Following the completion of the sale, the vice president now directly owns 21,786 shares of the company's stock, valued at $2,657,456.28. This trade represents a 8.05% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, Director Daniel K. Podolsky sold 1,819 shares of the business's stock in a transaction on Monday, March 31st. The shares were sold at an average price of $116.46, for a total transaction of $211,840.74. Following the sale, the director now directly owns 35,737 shares in the company, valued at $4,161,931.02. The trade was a 4.84% decrease in their position. The disclosure for this sale can be found here.

About Agilent Technologies

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.